Unusual Metastasis From Breast Cancer: Case Report

Review began 09/09/2021

Review ended 10/12/2021

Published 10/13/2021

© Copyright 2021

Jaouani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Laila Jaouani ¹, Adil Zaimi ¹, Ouissam Al Jarroudi ¹, Sami Aziz Brahmi ¹, Said Afqir ¹

1. Medical Oncology, Mohammed VI University Hospital, Oujda, MAR

Corresponding author: Laila Jaouani, drleila-jaouani@hotmail.com

Abstract

Metastatic breast cancer among young women represents a serious public health issue. The most frequent sites of dissemination are bone, liver, lung, lymph nodes and brain. Bladder location is extremely unusual. We present the case of a 33-year-old female who was receiving palliative chemotherapy for bilateral metastatic invasive lobular cancer. Following episodes of macroscopic hematuria, a CT scan was performed, which revealed a *suspicious* thickening of the bladder wall. After an endoscopic resection with immunohistological analysis, the diagnosis was confirmed. Voiding symptoms in a woman with a history of breast cancer should be evaluated to rule out a secondary urinary tract lesion. As soon as the diagnosis is determined, appropriate therapy should be initiated.

Categories: Pathology, Radiology, Oncology

Keywords: transurethral resection, bladder metastases, cystoscopy, hematuria, breast carcinoma

Introduction

Currently, breast cancer is the most common cancer affecting women worldwide, and its incidence is steadily increasing with 2.3 million women being newly diagnosed each year [1]. While significant progress has been achieved in breast cancer care and treatment results remain better, unfortunately breast cancer remains the second leading cause of cancer mortality among women in all countries, with 685,000 deaths each year [2]. In Morocco, breast cancer is a major public health problem, According to the World Health Organization cancer registry "GLOBOCAN 2020"; 11747 (38.9% of all cancers) new cases were diagnosed [3]. In 2012, the incidence rate in the eastern region of Morocco was 36.8 per 100,000. Lack of screening, late diagnosis, and locally advanced types are nevertheless prevalent, creating management challenges [4]. The most common sites of reported metastases are bone, liver, and lung, as well as lymph nodes and the brain [5]. Only a few cases of bladder metastases have been described in the literature [6]. The most common symptoms are cystitis and macroscopic hematuria. To distinguish primary bladder cancer from a secondary bladder metastasis from breast cancer, a cystoscopy with biopsy is required. We report a new case of bilateral breast cancer with a bladder metastasis occurring during treatment.

Case Presentation

A 33-year-old female patient with no previous significant history. The initial symptomatology was marked by the onset of dyspnea stage II. A chest X-ray performed showed a right pleural effusion. Pleural tuberculosis was evoked in the first place, considering the endemic character of this pathology in our country. A thoracentesis with cytobacteriological study was performed and revealed no bacterial infection. Investigations were continued by carrying out a staging thoracic-abdominal-pelvic CT scan that showed secondary hepatic, pleural and bone localizations.

The clinical examination revealed a patient with bad performance status, presenting with bilateral and multifocal breast lumps. the left breast lumps localised in the lower inner quadrant and in the upper outer quadrant measuring 35 mm and 30 mm, the right breast characterised by the presence of two lumps in the upper inner and outer quadrant measuring 15 mm and 35 mm with a bilateral axillary lymphadenopathy which was suspicious of malignancy. Mammography and ultrasound revealed breast lesions, classified as category five of the breast imaging-reporting and data system (BI-RADS 5). A biopsy with anatomopathological and immunohistochemical study confirmed the diagnosis of bilateral invasive lobular carcinoma: Scarff-Bloom-Richardson (SBR) grade II, estrogen receptor (ER) at 100%, progesterone receptor (PR) at 20%, human epidermal growth factor receptor 2 (HER2) negative, KI67 at 5%. The initial cancer antigen 15-3 (CA15-3) biomarker was higher with 127 IU/ml.

The patient was treated with anthracycline 60 mg/m², cyclophosphamide 600 mg/m² and zoledronic acid 4 mg every 21 days as a first-line systemic chemotherapy. After six cycles, the CA15-3 decreased to 7.17 IU/ml with favorable evolution of target lesions. The patient began maintenance therapy with Tamoxifen + Medical castration using monthly Goserelin 3.6 mg subcutaneously.

Ten months later, the patient was suffering from macroscopic hematuria, pollakiuria and dysuria. The urine

How to cite this article

Jaouani L, Zaimi A, Al Jarroudi O, et al. (October 13, 2021) Unusual Metastasis From Breast Cancer: Case Report. Cureus 13(10): e18737. DOI 10.7759/cureus.18737

cytology was negative for malignant cells. The CA15-3 at 25 IU/ml. As part of the evaluation, the patient underwent a second thoraco-abdomino-pelvic CT scan which showed stability of the initial lesions and the appearance of a bladder wall thickening (Figure 1). Following an abdominal ultrasound, cystoscopy was performed and a budding mass in the bladder wall was found. The immunohistochemical profile of the biopsies was compatible with a bladder localization of a poorly differentiated carcinomatous process of mammary origin (anti-CK7+, anti-CK20-, anti-P63-, anti-GATA3+, ER+, PR+, HER2) not overexpressed (Figures 2, 3)

FIGURE 1: Axial (A) and sagittal (B) contrast-enhanced CT images of the abdomen and pelvis, showing a bladder wall thickening.

FIGURE 2: Invasive lobular carcinoma of the breast infiltrating the bladder mucosa.

FIGURE 3: Immunohistochemical findings.

The case was discussed in a multidisciplinary consultation meeting. The indication for hemostatic radiotherapy was not retained because the patient was hemodynamically stable without massive bleeding and second-line chemotherapy was started based on docetaxel 75 mg/m² associated with oral tranexamic acid for hemostatic purposes. The patient died of interstitial lung disease 15 days after three cycles of chemotherapy.

Discussion

Bladder metastases from solid tumors are very rare and unusual. They represent less than 2% of bladder cancers [7]. In 1950, Abrams et al analyzed, for the first time, the incidence of metastases by autopsy in 1,000 patients. Out of 167 patients with metastatic breast cancer, only four patients had bladder localizations, representing 2.4% versus 77.2% for the lung localization [8]. To date, 65 cases have been published in the literature [6].

Extension to the bladder frequently occurs by contiguity from a pelvic organ such as prostate, cervical and colon cancer. Metastasis from a distant organ is rarely reported in the literature [9,10]. It is thought to be due to hematogenous migration of tumor emboli via the pulmonary circulation [11,12]. Pontes and Oldford propose the hypothesis of bladder involvement with retroperitoneal origin [12].

There are two main histologic subtypes of breast cancer: invasive ductal carcinoma (IDC) accounting for 90% and invasive lobular carcinoma (ILC) for 5%-15% [13]. Although they have a common tropism to bone (50%), brain (16%), lung (17%), and liver (6%), the lobular subtype has an affinity to the gastrointestinal tract, peritoneum and retroperitoneum [14-16]. This different metastatic potential is explained by the size and shape of ILC tumor cells and the loss of expression of E-cadherin; a molecule responsible for cell cohesion.

Bladder involvement is either synchronous or metachronous with breast cancer. In the majority of cases, the bladder location is part of a multi-metastatic cancer; solitary forms have also been reported [17-19]. The delay in the occurrence of bladder metastasis during the course of the disease is very variable; it can be up to thirty years after the diagnosis of breast cancer [18]. In our case, the patient showed a synchronous bladder metastasis of breast cancer during treatment.

Bladder metastasis poses a problem of differential diagnosis with a primary bladder tumor, clinically, biologically and radiologically. Differentiation between a poorly differentiated or undifferentiated primitive bladder cancer and a bladder metastasis of another primary carcinoma can be difficult [20]. Biopsy with pathological and possibly immunohistochemical study is the key to diagnosis.

The clinical presentation is pleomorphic, ranging from a silent bladder metastasis discovered incidentally during the radiological check-up [20] to a relevant symptomatology. The major warning sign is microscopic and then macroscopic hematuria [21]. Irritative symptoms include pollakiuria, dysuria, polyuria, incontinence and low back pain [18,22]. Renal failure on bilateral hydronephrosis may be a telling complication [23,24]. Urinary disorders depend on the degree of invasion of the bladder wall. Irritative signs appear secondary to detrusor infiltration and may precede hematuria. The appearance of urinary symptoms in a patient with a history of breast cancer should be carefully investigated. Given the risk of delayed diagnosis of bladder metastasis in the case of patients with post-chemotherapy hematuria or cystitis, including cyclophosphamide.

When a patient with breast cancer is experiencing urinary problems, a bladder ultrasound is the first line of investigation. A normal urine cytology does not exclude the diagnosis of a bladder tumor. A CT or MRI scan may also be performed to explore the upper urinary tract in patients with hematuria [25]. PET scan is useful for detecting local recurrence and distant metastases but it has somewhat limited capacity to detect bladder hypermetabolism. In the initial management of breast cancer, the role of CA 15-3 is highly controversial [26]. Its effectiveness in the early diagnosis of breast cancer metastases is recognized. There is a good

correlation between the biological and clinical evolution of patients during the treatment of their metastases [27].

Cystoscopy is the gold standard examination, performed in the office with a sterile urinalysis. It may find an irregular mass, especially lateral and posterior, a thickened bladder wall and sometimes small polyps [18,28]. Transurethral resection is both a diagnostic and therapeutic procedure. It allows the definitive diagnosis to be established.

In our case, the diagnosis of bladder metastasis was based on the immunohistochemical study which complements the morphological study. The first step of the decision algorithm is based on a battery of markers. The low molecular weight cytokeratins CK7 and CK20 allow a rough orientation towards a primary tumor [29]. CK7 positivity, CK20 negativity and GATA3 positivity suggested the mammary origin of the bladder involvement. GATA3 is expressed in 92% to 100% of ductal and lobular breast cancer. The presence of hormone receptors (ER 20%, PR 10%) and HER2 negativity confirmed the diagnosis of bladder metastasis from a mammary origin. In the literature, studies have shown that a discordance in hormone receptor expression has been reported between primary breast cancer and bladder metastasis [17,18,30,31].

The treatment of metastatic breast cancer has undergone tremendous progress in recent years. Chemotherapy is no longer the only standard treatment for visceral crisis. With the advent of immunotherapy [32], PARP inhibitors [33], CDK4/6 inhibitors and endocrine therapy, progression-free survival and overall survival have been improved [34]. Currently, the combination of CDK4/6 inhibitors (Palbociclib, abemaciclib or ribociclib) and aromatase inhibitor or Fulvestrant [35-37] remains the first-line treatment for hormone receptor-positive metastatic breast cancer (RH+) according to the European Society for Medical Oncology "ESMO" and National Comprehensive Cancer Network "NCCN" guidelines [38].

Our patient received first-line anthracycline-based regimen, which has proven its effectiveness in terms of objective response according to the first meta-analysis by Fossati et al. [39], and zoledronic acid for delaying skeletal events [40]. The duration of chemotherapy in the metastatic setting is until disease progression or excessive toxicity. Maintenance with hormone therapy has shown a good result in terms of progression-free survival and overall survival with fewer side effects [41].

The transurethral resection of the bladder (TURB) has a diagnostic and therapeutic interest while bladder irrigation with tranexamic acid is also effective in emergency situations. Palliative radiotherapy is useful for local control of the disease and especially for haemostatic purposes [42,43].

Unfortunately on the whole, the prognosis of breast cancer with bladder metastasis is poor. Overall survival varies between one month and two years [44]. This is the case of our patient who died four months after diagnosis.

Conclusions

Although secondary bladder tumors are uncommon, they should be suspected in any patient with a history of breast cancer who presented urinary disorders. The most common symptom of the illness is hematuria. Cystoscopy with biopsy and immunohistochemistry is the critical stage in the diagnostic procedure for distinguishing between primary and secondary malignancy.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021, 71:209-49. [10.3322/caac.21660](https://doi.org/10.3322/caac.21660)
2. Lei S, Zheng R, Zhang S, et al.: Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. *Cancer Commun.* 2021, [10.1002/cac2.12207](https://doi.org/10.1002/cac2.12207)
3. The Global Cancer Observatory . (2021). <https://gco.iarc.fr/today/data/factsheets/populations/504-morocco-fact-sheets.pdf>.
4. Elidrissi Errahhali M, Elidrissi Errahhali M, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M: First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. *BMC Womens Health.* 2017, 17:3. [10.1186/s12905-016-0361-z](https://doi.org/10.1186/s12905-016-0361-z)

5. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L: The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. *BMC Cancer*. 2019, 19:1091. [10.1186/s12885-019-6311-z](https://doi.org/10.1186/s12885-019-6311-z)
6. Karjol U, Jonnada P, Cherukuru S, Chandranath A: Bladder metastasis from breast cancer: a systematic review. *Cureus*. 2020, 12:e7408. [10.7759/cureus.7408](https://doi.org/10.7759/cureus.7408)
7. Karaosmanoglu AD, Onur MR, Karcaaltincaba M, Akata D, Ozmen MN: Secondary Tumors of the Urinary System: An Imaging Conundrum. *Korean J Radiol*. 2018, 19:742-751.
8. Abrams HL, Spiro R, Goldstein N: Metastases in carcinoma; analysis of 1000 autopsied cases. *Cancer*. 1950, 3:74-85. [10.1002/1097-0142\(1950\)3:1<74::aid-cnrc2820030111>3.0.co;2-7](https://doi.org/10.1002/1097-0142(1950)3:1<74::aid-cnrc2820030111>3.0.co;2-7)
9. Petraki C, Vaslamatzis M, Argyrakos T, Petraki K, Strataki M, Alexopoulos C, Sotsiou F: Tumor to tumor metastasis: report of two cases and review of the literature. *Int J Surg Pathol*. 2003, 11:127-35. [10.1177/106689690301100214](https://doi.org/10.1177/106689690301100214)
10. Karaosmanoglu AD, Onur MR, Karcaaltincaba M, Akata D, Ozmen MN: Secondary tumors of the urinary system: an imaging conundrum. *Korean J Radiol*. 2018, 19:742-51. [10.3348/kjr.2018.19.4.742](https://doi.org/10.3348/kjr.2018.19.4.742)
11. Goldstein AG: Metastatic carcinoma to the bladder. *J Urol*. 1967, 98:209-15. [10.1016/s0022-5347\(17\)62857-x](https://doi.org/10.1016/s0022-5347(17)62857-x)
12. Pontes JE, Oldford JR: Metastatic breast carcinoma to the bladder. *J Urol*. 1970, 104:839-42. [10.1016/s0022-5347\(17\)61848-2](https://doi.org/10.1016/s0022-5347(17)61848-2)
13. Arps DP, Healy P, Zhao L, Kleer CG, Pang JC: Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast. *Breast Cancer Res Treat*. 2013, 138:719-26. [10.1007/s10549-013-2493-2](https://doi.org/10.1007/s10549-013-2493-2)
14. Patanaphan V, Salazar OM, Risco R: Breast cancer: metastatic patterns and their prognosis. *South Med J*. 1988, 81:1109-12.
15. Rakha EA, Patel A, Powe DG, et al.: Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. *Am J Surg Pathol*. 2010, 34:1472-9. [10.1097/PAS.0b013e3181f01916](https://doi.org/10.1097/PAS.0b013e3181f01916)
16. Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. *Surgery*. 1993, 114:637-41.
17. Zagha RM, Hamawy KJ: Solitary breast cancer metastasis to the bladder: an unusual occurrence. *Urol Oncol*. 2007, 25:236-9. [10.1016/j.urolonc.2006.05.013](https://doi.org/10.1016/j.urolonc.2006.05.013)
18. Feldman PA, Madeb R, Naroditsky I, Halachmi S, Nativ O: Metastatic breast cancer to the bladder: a diagnostic challenge and review of the literature. *Urology*. 2002, 59:138. [10.1016/s0090-4295\(01\)01489-3](https://doi.org/10.1016/s0090-4295(01)01489-3)
19. Jordan LA, Green L: Late breast cancer metastasis to the urinary bladder presenting with bilateral hydronephrosis. *Radiol Case Rep*. 2018, 13:1238-41. [10.1016/j.radcr.2018.08.029](https://doi.org/10.1016/j.radcr.2018.08.029)
20. Cormio L, Sanguedolce F, Di Fino G, et al.: Asymptomatic bladder metastasis from breast cancer. *Case Rep Urol*. 2014, 2014:672591. [10.1155/2014/672591](https://doi.org/10.1155/2014/672591)
21. Xiao GQ, Chow J, Unger PD: Metastatic tumors to the urinary bladder: clinicopathologic study of 11 cases. *Int J Surg Pathol*. 2012, 20:342-8. [10.1177/1066896911428736](https://doi.org/10.1177/1066896911428736)
22. Luczyńska E, Pawlik T, Chwalibóg A, Anioł J, Ryś J: Metastatic breast cancer to the bladder: case report and review of literature. *J Radiol Case Rep*. 2010, 4:19-26. [10.3941/jrcr.v4i5.395](https://doi.org/10.3941/jrcr.v4i5.395)
23. Vulcano E, Montesano M, Battista C, Carino R, Perrone G, Vincenzi B, Altomare V: Urinary complications from breast cancer metastasis: case report and review of the literature. *G Chir*. 2010, 31:243-5.
24. Shah KG, Modi PR, Rizvi J: Breast carcinoma metastasizing to the urinary bladder and retroperitoneum presenting as acute renal failure. *Indian J Urol*. 2011, 27:135-6. [10.4103/0970-1591.78421](https://doi.org/10.4103/0970-1591.78421)
25. Qi Y, Tang D: Commentary: Bladder cancer. *Curr Urol*. 2021, 15:1. [10.1097/CU9.0000000000000003](https://doi.org/10.1097/CU9.0000000000000003)
26. Gonsaud B, Goussot V, Berriolo-Riedinger A, et al.: Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer. *Ann Biol Clin*. 2017, 75:421-9. [10.1684/abc.2017.1257](https://doi.org/10.1684/abc.2017.1257)
27. Riedinger J-M: Intérêt des marqueurs tumoraux : quelle place pour l'ACE et le CA 15-3 ? . *Médecine Nucléaire*. 2010, 34:4451. [10.1016/j.mednuc.2009.11.006](https://doi.org/10.1016/j.mednuc.2009.11.006)
28. Ramsey J, Beckman EN, Winters JC: Breast cancer metastatic to the urinary bladder. *Ochsner J*. 2008, 8:208-12.
29. Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M: Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. *Cancers*. 2018, 10:10.3390/cancers10040108
30. Liu H, Shi J, Wilkerson ML, Lin F: Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. *Am J Clin Pathol*. 2012, 138:57-64. [10.1309/AJCP5UAFMSA9ZQBZ](https://doi.org/10.1309/AJCP5UAFMSA9ZQBZ)
31. Miettinen M, McCue PA, Sarlomo-Rikala M, et al.: GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. *Am J Surg Pathol*. 2014, 38:13-22. [10.1097/PAS.0b013e3182a0218f](https://doi.org/10.1097/PAS.0b013e3182a0218f)
32. Schmid P, Adams S, Rugo HS, et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018, 379:2108-21. [10.1056/NEJMoa1809615](https://doi.org/10.1056/NEJMoa1809615)
33. Cortesi L, Rugo HS, Jackisch C: An overview of PARP inhibitors for the treatment of breast cancer. *Target Oncol*. 2021, 16:255-82. [10.1007/s11523-021-00796-4](https://doi.org/10.1007/s11523-021-00796-4)
34. Tripathy D, Im SA, Colleoni M, et al.: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol*. 2018, 19:904-15. [10.1016/S1470-2045\(18\)30292-4](https://doi.org/10.1016/S1470-2045(18)30292-4)
35. Hortobagyi GN, Stemmer SM, Burris HA, et al.: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol*. 2019, 30:1842. [10.1093/annonc/mdz215](https://doi.org/10.1093/annonc/mdz215)
36. Johnston S, Martin M, Di Leo A, et al.: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer*. 2019, 5:5. [10.1038/s41523-018-0097-z](https://doi.org/10.1038/s41523-018-0097-z)
37. Rugo HS, Finn RS, Diéras V, et al.: Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat*. 2019, 174:719-29. [10.1007/s10549-018-05125-4](https://doi.org/10.1007/s10549-018-05125-4)
38. Cardoso F, Paluch-Shimon S, Senkus E, et al.: 5th ESO-ESMO international consensus guidelines for

- advanced breast cancer (ABC 5). *Ann Oncol.* 2020, 31:1623-49. [10.1016/j.annonc.2020.09.010](https://doi.org/10.1016/j.annonc.2020.09.010)
39. Fossati R, Confalonieri C, Torri V, et al.: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. *J Clin Oncol.* 1998, 16:3439-60. [10.1200/JCO.1998.16.10.3439](https://doi.org/10.1200/JCO.1998.16.10.3439)
40. Luo Q, Men P, Liu Z, Zhai S, Jiang M: Is de-escalated bisphosphonates therapy a suitable alternative to standard dosing in malignant tumor patients with bone metastases: a systematic review and meta-analysis. *Front Oncol.* 2019, 9:774. [10.3389/fonc.2019.00774](https://doi.org/10.3389/fonc.2019.00774)
41. Yu Y, Wang Y, Gao Q, et al.: Benefits and risks from maintenance therapy after first-line chemotherapy in patients with metastatic breast cancer. *J Clin Oncol.* 2018, 36:1088-1088. [10.1200/JCO.2018.36.15_suppl.1088](https://doi.org/10.1200/JCO.2018.36.15_suppl.1088)
42. Moharamzadeh P, Ojaghahighi S, Amjadi M, Rahmani F, Farjamnia A: Effect of tranexamic acid on gross hematuria: a pilot randomized clinical trial study. *Am J Emerg Med.* 2017, 35:1922-5. [10.1016/j.ajem.2017.09.012](https://doi.org/10.1016/j.ajem.2017.09.012)
43. Ogita M, Kawamori J, Yamashita H, Nakagawa K: Palliative radiotherapy for gross hematuria in patients with advanced cancer. *Sci Rep.* 2021, 11:9533. [10.1038/s41598-021-88952-8](https://doi.org/10.1038/s41598-021-88952-8)
44. Poulakis V, Witzsch U, de Vries R, Becht E: Metastatic breast carcinoma to the bladder: 5-year followup . *J Urol.* 2001, 165:905.